Allianz Asset Management
AXSM icon

Allianz Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Allianz Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Buy
11,021
+7,021
+176% +$1.52M ﹤0.01% 1642
2026
Q1 		$676K Buy
4,000
+2,700
+208% +$466K ﹤0.01% 1799
2025
Q4 		$237K Buy
+1,300
New +$181K ﹤0.01% 1919
2025
Q3 		– Sell
-6,300
Closed -$658K – 2006
2025
Q2 		$658K Buy
6,300
+1,919
+44% +$203K ﹤0.01% 1762
2025
Q1 		$511K Sell
4,381
-1,114
-20% -$127K ﹤0.01% 1870
2024
Q4 		$465K Buy
+5,495
New +$505K ﹤0.01% 1885
2021
Q3 		– Sell
-10,760
Closed -$726K – 2542
2021
Q2 		$726K Buy
+10,760
New +$646K ﹤0.01% 1873
2021
Q1 		– Sell
-6,162
Closed -$502K – 2163
2020
Q4 		$502K Sell
6,162
-4,837
-44% -$362K ﹤0.01% 1630
2020
Q3 		$784K Buy
+10,999
New +$857K ﹤0.01% 1498
2020
Q2 		– Sell
-50,794
Closed -$2.99M – 2392
2020
Q1 		$2.99M Buy
50,794
+20,244
+66% +$1.65M ﹤0.01% 1387
2019
Q4 		$3.16M Sell
30,550
-641
-2% -$25.9K ﹤0.01% 1686
2019
Q3 		$631K Sell
31,191
-36,182
-54% -$930K ﹤0.01% 2295
2019
Q2 		$1.74M Buy
+67,373
New +$1.35M ﹤0.01% 1929
2018
Q1 		– Sell
-125,670
Closed -$704K – 2622
2017
Q4 		$704K Hold
125,670
– – ﹤0.01% 2333
2017
Q3 		$697K Hold
125,670
– – ﹤0.01% 2340
2017
Q2 		$723K Sell
125,670
-2,530
-2% -$10.6K ﹤0.01% 2320
2017
Q1 		$500K Buy
128,200
+18,110
+16% +$86.5K ﹤0.01% 2397
2016
Q4 		$743K Hold
110,090
– – ﹤0.01% 2294
2016
Q3 		$847K Sell
110,090
-9,150
-8% -$69.3K ﹤0.01% 2251
2016
Q2 		$899K Hold
119,240
– – ﹤0.01% 2198
2016
Q1 		$1.02M Buy
119,240
+2,075
+2% +$19K ﹤0.01% 2074
2015
Q4 		$1.08M Buy
+117,165
New +$1.03M ﹤0.01% 1949

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allianz Asset Management's AXSM Position: Q2 2026 in Review

Allianz Asset Management increased its Axsome Therapeutics (AXSM) stake by 176% in Q2 2026, buying an estimated $1.52M and bringing the position to 11,021 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1642.

Allianz Asset Management first reported a position in AXSM in Q4 2015 and has held it in 22 quarters since. The position peaked at $3.16M in Q4 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Allianz Asset Management held 11,021 shares of Axsome Therapeutics worth $2.7M as of Q2 2026.
  • Allianz Asset Management bought 7,021 Axsome Therapeutics shares in Q2 2026, an estimated $1.52M.
  • Axsome Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1642 holding.
  • Allianz Asset Management first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 22 quarters since.
  • Allianz Asset Management's Axsome Therapeutics position peaked at $3.16M in Q4 2019.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.